Endothelin News
Information on endothelin discovery, recent developments in endothelin research,
clinical trials, ERA drug development, and other areas of endothelin science.
For most recent information and updates on endothelin research, visit Endothelins.com on Facebook
Actelion SERAPHIN Phase III trial in PAH with ERA macitentan meets primary endpoint and reduces morbidity/mortality
Comprehensive article by Rachael Moeller-Gorman on current endothelin research
A number of educational videos on endothelin and its receptors
Educational video on endothelin and its receptors in physiology and cell growth
New book on endothelin in kidney physiology and disease
An online version of a lecture on endothelin in hypertension by David Webb, University of Edinburgh
Endothelin as a cause of protein loss due kidney disease
Discovery of a new role of endothelin in bladder cancer metastasis
New pathogenic role of endothelin revealed in sickle cell disease
New approaches needed in PAH trials
Current state of clinical therapy with endothelin antagonists
Research needed to understand endothelin receptor function
Endothelin peptide information on the Wellcome Trust Sanger Institute website
New approaches needed in PAH trials
Avosentan trial in diabetic nephropathy stopped early in interest of patient safety
Endothelin receptor antagonist (ERA) therapy in pulmonary hypertension
2nd Symposium on Endothelin Antagonism 1999 in Zurich, Switzerland
Endothelin in kidney disease due to high blood pressure
Information about the endothelin gene and its medical relevance in the Wikigenes database
Endothelin antagonists for cancer and cardiovascular diseases
Actelion SERAPHIN Phase III trial in PAH with ERA macitentan meets primary endpoint and reduces morbidity/mortality
Lack of effect of intravenous ERA clazosentan on mortality in patients with subarachnoid hemorrhage
Liver function tests no longer required for ambrisentan (Letairis®) because of good drug safety
Abbott Phase IIa study finds therapeutic benefit for the ERA atrasentan in patients with diabetic nephropathy
AstraZeneca Phase III ERA Trial in non-metastatic castrate resistant prostate cancer stopped early
Abbott Phase IIa study finds therapeutic benefit for the ERA atrasentan in patients with diabetic nephropathy
Pfizer withdraws the ERA sixtaxentan (Thelin®) from market - possible links to fatal liver toxicity
Gilead stops Phase III clinical trial with ambrisentan (Letairis®) in idiopathic pulmonary fibrosis patients with PAH
Speedel ERA avosentan causes serious side effects including heart failure in patients with diabetic nephropathy
Gilead decides to discontinue Phase III trial with ambrisentan in patients with resistant hypertension
Gilead Phase III clinical trial with ERA darusentan finds efficacy in patients with resistant hypertension
Speedel trial with ERA avosentan suggests benefit in stopped trial in diabetic nephropathy
Study results from ARIES1, ARIES-2, and ARIES-3 Studies presented
Pfizer buys Encysive for $195 million
Letairis receives FDA approval for pulmonary hypertension
Pharmacopeia reports first clinical results with dual endothelin/angiotensin antagonist
Pharmacopeia starts hypertension trial with dual endothelin/angiotensin antagonist
AstraZeneca ERA trial suggests treatment extends prostate cancer survival
Avosentan trial in diabetic nephropathy stopped early in interest of patient safety
Texas Biotechnology anncounces name change to Encysive Pharmaceuticals
